SMU-L11
SMU-L11 is a specific TLR7 agonist (EC50=0.024 μM), which recruits MyD88 adapter protein and activates downstream NF-κB and MAPK signaling pathways. In murine models, SMU-L11 significantly enhances immune cell activation and promotes the proliferation of CD4+ T and CD8+ T cells, thereby directly killing tumor cells and inhibiting tumor growth. SMU-L11 can be used for cancer research, and also has the potential for studying immune system diseases[1].
Product Specifications
UNSPSC
12352005
Target
MAPKAPK2 (MK2) ; NF-κB; Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/smu-l11.html
Purity
99.64
Solubility
10 mM in DMSO
Smiles
CCCCC1=NC2=C(N1CC3CCOC3)C4=CC=CC=C4N=C2N
Molecular Formula
C19H24N4O
Molecular Weight
324.42
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
TLR7
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
G0 Protein alpha (GNAO1) (345-354) Rabbit Polyclonal Antibody
